Sarepta Therapeutics, Inc. (SRPT)
NASDAQ: SRPT · Real-Time Price · USD
36.37
+0.10 (0.28%)
At close: May 12, 2025, 4:00 PM
36.62
+0.25 (0.69%)
After-hours: May 12, 2025, 7:59 PM EDT
Sarepta Therapeutics Stock Forecast
Stock Price Forecast
The 23 analysts with 12-month price forecasts for Sarepta Therapeutics stock have an average target of 131.09, with a low estimate of 40 and a high estimate of 230. The average target predicts an increase of 260.43% from the current stock price of 36.37.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Sarepta Therapeutics stock from 23 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 5 | 5 | 7 |
| Buy | 13 | 13 | 12 | 11 | 12 | 11 |
| Hold | 1 | 1 | 1 | 3 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 2 | 2 | 2 | 1 | 1 |
| Total | 21 | 22 | 21 | 21 | 22 | 23 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $115 → $100 | Buy | Maintains | $115 → $100 | +174.95% | May 8, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $87 → $58 | Hold | Maintains | $87 → $58 | +59.47% | May 7, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $178 → $100 | Strong Buy | Maintains | $178 → $100 | +174.95% | May 7, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $112 → $98 | Strong Buy | Maintains | $112 → $98 | +169.45% | May 7, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $110 → $70 | Buy | Maintains | $110 → $70 | +92.47% | May 7, 2025 |
Financial Forecast
Revenue This Year
3.13B
from 1.90B
Increased by 64.51%
Revenue Next Year
3.83B
from 3.13B
Increased by 22.40%
EPS This Year
7.17
from 2.34
Increased by 206.79%
EPS Next Year
12.68
from 7.17
Increased by 76.80%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.8B | 4.6B | 6.3B | ||
| Avg | 3.1B | 3.8B | 4.1B | ||
| Low | 2.6B | 2.9B | 2.9B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 100.7% | 47.7% | 64.6% | ||
| Avg | 64.5% | 22.4% | 8.1% | ||
| Low | 38.9% | -7.3% | -25.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 15.18 | 16.24 | 30.62 | ||
| Avg | 7.17 | 12.68 | 14.91 | ||
| Low | 1.09 | 7.64 | 5.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 549.3% | 126.4% | 141.4% | ||
| Avg | 206.8% | 76.8% | 17.6% | ||
| Low | -53.5% | 6.6% | -60.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.